<DOC>
	<DOCNO>NCT01279018</DOCNO>
	<brief_summary>Breast cancer treatment many patient follow sequelae , persistent pain , sensory disturbance , lymphedema reduce physical function . These undesired consequence treatment major clinical problem , persistent pain affect 25-60 % , sensory disturbance 20-80 % , lymphedema 2-86 % reduced physical function 13-28 % patient . Development persistent pain breast cancer treatment , involve complex pathophysiology involve pre- , intra- postoperative factor . Several risk factor development persistent pain breast cancer treatment identify ; young age , psychosocial factor , surgical procedure radiation therapy . Neurotoxicity well know attribute many chemotherapeutic agent , taxanes . The purpose nationwide study retrospectively examine cohort breast cancer patient treat docetaxel , clarify docetaxel may influence prevalence intensity persistent pain sequela .</brief_summary>
	<brief_title>Persistent Pain After Breast Cancer Treatment With Docetaxel</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Lymphedema</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Treated primary breast cancer Denmark 20072008 Age 1880 year No recurrent cancer Female Previous breast surgery side ( include plastic reconstructive surgery ) Bilateral breast surgery Recurrent cancer metastatic cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Persistent postsurgical pain</keyword>
	<keyword>breast cancer</keyword>
	<keyword>postmastectomy pain syndrome</keyword>
	<keyword>neuropathic pain</keyword>
</DOC>